Skip to main content
Top
Published in: Supportive Care in Cancer 11/2016

01-11-2016 | Original Article

Outcome prognostic factors in inoperable malignant bowel obstruction

Authors: Margarita Romeo, Maria de los LLanos Gil, José Luís Cuadra Urteaga, Laia Vilà, Sara Ahlal, Alberto Indacochea, Núria Pardo, Joaquim Radua, Albert Font, Albert Tuca

Published in: Supportive Care in Cancer | Issue 11/2016

Login to get access

Abstract

Purpose

Inoperable malignant bowel obstruction (MBO), a severe complication of peritoneal carcinomatosis, has a low desobstruction rate (30–40 %) and end-of-life decision-making is hampered by the lack of known prognostic factors. This study aimed to explore prognostic factors for desobstruction in MBO.

Methods

All patients with inoperable MBO admitted in our large oncology hospital between 2010 and 2013 were treated following a clinical protocol based on antiemetics, steroids and two antisecretories, octreotide, and hyoscine butylbromide. Two prognostic factor analyses using logistic regressions were performed, one based on data from day 1 of admission and the other on data from day 8.

Results

Forty-five patients were included. Frequency of desobstruction was 48.9 %. In the analysis of prognostic factors on day 1, MBO episodes derived from functional physiopathologic mechanisms (vs. mechanic or mixed) were more prone to resolve (p < 0.001 corrected for multiple comparisons). Considering patients alive with persistent obstruction on day 8, a better clinical condition was the variable more associated with desobstruction, but without statistical significance after correction for multiple comparisons.

Conclusions

A functional physiopathologic mechanism of MBO development may be an early prognostic factor for desobstruction. A high proportion of desobstruction was observed, suggesting that the combination of antisecretories with different mechanism of action warrants further investigation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Anthony T, Baron T, Mercadante S, Green S, Chi D, Cunningham J, Herbst A, Smart E, Krouse RS (2007) Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manag 34:S49–S59CrossRef Anthony T, Baron T, Mercadante S, Green S, Chi D, Cunningham J, Herbst A, Smart E, Krouse RS (2007) Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction. J Pain Symptom Manag 34:S49–S59CrossRef
2.
go back to reference Tuca A, Guell E, Martinez-Losada E, Codorniu N (2012) Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res 4:159–169CrossRefPubMedPubMedCentral Tuca A, Guell E, Martinez-Losada E, Codorniu N (2012) Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res 4:159–169CrossRefPubMedPubMedCentral
3.
go back to reference Feuer DJ, Broadley K. (2004) Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. In: The Cochrane Library. Wiley, Chichester Feuer DJ, Broadley K. (2004) Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. In: The Cochrane Library. Wiley, Chichester
4.
go back to reference Mercadante S, Ferrera P, Villari P, Marrazzo A (2004) Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manag 28:412–416CrossRef Mercadante S, Ferrera P, Villari P, Marrazzo A (2004) Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manag 28:412–416CrossRef
5.
go back to reference Fallon MT (1994) The physiology of somatostatin and its synthetic analogue, octreotide. Eur J Palliat Care 1:20–22 Fallon MT (1994) The physiology of somatostatin and its synthetic analogue, octreotide. Eur J Palliat Care 1:20–22
6.
go back to reference Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L (2000) Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8:188–191CrossRefPubMed Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L (2000) Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8:188–191CrossRefPubMed
7.
go back to reference Peng X, Wang P, Li S, Zhang G, Hu S (2015) Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol 13:50CrossRefPubMedPubMedCentral Peng X, Wang P, Li S, Zhang G, Hu S (2015) Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol 13:50CrossRefPubMedPubMedCentral
8.
go back to reference Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A (2000) Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manag 19:23–34CrossRef Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A (2000) Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manag 19:23–34CrossRef
9.
go back to reference Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L (2002) Comparison of octreotide administration vs. conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial. Anticancer Res 22:1187–1192PubMed Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L (2002) Comparison of octreotide administration vs. conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial. Anticancer Res 22:1187–1192PubMed
10.
go back to reference Mercadante S, Porzio G (2012) Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol 83:388–392CrossRefPubMed Mercadante S, Porzio G (2012) Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol 83:388–392CrossRefPubMed
11.
go back to reference De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V (1991) Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manag 6:484–486CrossRef De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V (1991) Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manag 6:484–486CrossRef
12.
go back to reference O’Connor B, Creedon B (2011) Pharmacological treatment of bowel obstruction in cancer patients. Expert Opin Pharmacother 12:2205–2214CrossRefPubMed O’Connor B, Creedon B (2011) Pharmacological treatment of bowel obstruction in cancer patients. Expert Opin Pharmacother 12:2205–2214CrossRefPubMed
13.
go back to reference Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L (2012) Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 30:4337–4343CrossRefPubMed Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L (2012) Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 30:4337–4343CrossRefPubMed
14.
go back to reference Mercadante S (1998) Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction. J Pain Symptom Manag 16:278–280CrossRef Mercadante S (1998) Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction. J Pain Symptom Manag 16:278–280CrossRef
15.
go back to reference Laval G, Arvieux C, Stefani L, Villard ML, Mestrallet JP, Cardin N (2006) Protocol for the treatment of malignant inoperable bowel obstruction: a prospective study of 80 cases at Grenoble University Hospital Center. J Pain Symptom Manag 31:502–512CrossRef Laval G, Arvieux C, Stefani L, Villard ML, Mestrallet JP, Cardin N (2006) Protocol for the treatment of malignant inoperable bowel obstruction: a prospective study of 80 cases at Grenoble University Hospital Center. J Pain Symptom Manag 31:502–512CrossRef
16.
go back to reference Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K (2015) Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manag 49:814–821CrossRef Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K (2015) Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manag 49:814–821CrossRef
17.
go back to reference Porzio G, Aielli F, Verna L, Galletti B, Shoja ERG, Ficorella C (2011) Can malignant bowel obstruction in advanced cancer patients be treated at home? Support Care Cancer 19:431–433CrossRefPubMed Porzio G, Aielli F, Verna L, Galletti B, Shoja ERG, Ficorella C (2011) Can malignant bowel obstruction in advanced cancer patients be treated at home? Support Care Cancer 19:431–433CrossRefPubMed
18.
go back to reference Hisanaga T, Shinjo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, Kizawa Y, Maeno T, Shima Y, Hyodo I (2010) Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol 40:739–745CrossRefPubMed Hisanaga T, Shinjo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, Kizawa Y, Maeno T, Shima Y, Hyodo I (2010) Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol 40:739–745CrossRefPubMed
19.
go back to reference Tuca A, Martinez E, Guell E, Gomez Batiste X (2010) Malignant bowel obstruction. Med Clin (Barc) 135:375–381CrossRef Tuca A, Martinez E, Guell E, Gomez Batiste X (2010) Malignant bowel obstruction. Med Clin (Barc) 135:375–381CrossRef
20.
go back to reference Watari H, Hosaka M, Wakui Y, Nomura E, Hareyama H, Tanuma F, Hattori R, Azuma M, Kato H, Takeda N, Ariga S, Sakuragi N (2012) A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer. Int J Gynecol Cancer 22:692–696CrossRefPubMed Watari H, Hosaka M, Wakui Y, Nomura E, Hareyama H, Tanuma F, Hattori R, Azuma M, Kato H, Takeda N, Ariga S, Sakuragi N (2012) A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer. Int J Gynecol Cancer 22:692–696CrossRefPubMed
Metadata
Title
Outcome prognostic factors in inoperable malignant bowel obstruction
Authors
Margarita Romeo
Maria de los LLanos Gil
José Luís Cuadra Urteaga
Laia Vilà
Sara Ahlal
Alberto Indacochea
Núria Pardo
Joaquim Radua
Albert Font
Albert Tuca
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3299-7

Other articles of this Issue 11/2016

Supportive Care in Cancer 11/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine